UPDATED: Eli Lilly lops Alzheimer's and obesity assets from pipeline in Q4 update
In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was advancing a DACRA alongside tirzepatide, the active ingredient in Mounjaro and Zepbound, but the GLP-1 candidate emerged as the more promising program.
Hosted on MSN5h
Eli Lilly (NYSE:LLY) Reports Q4 In Line With Expectations, Full-Year Outlook Slightly Exceeds ExpectationsGlobal pharmaceutical company Eli Lilly (NYSE:LLY) in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The ...
Eli Lilly (NYSE: LLY) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...
Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...
Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 ...
Reports Q4 revenue $13.53B, consensus $13.43B. “2024 was a highly successful year for Lilly,” said David Ricks, Lilly’s chair and CEO. “We had ...
Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.
Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...
Lilly's fourth-quarter earnings, released before the market opened Thursday, surpassed analysts' expectations by millions.
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback